Researchers from the Icahn School of Medicine characterize the transcriptional splicing landscape of a prostate cancer cell line treated with a previously identified synergistic drug combination. They use a combination of third generation long-read RNA sequencing technology and short-read RNAseq to create a high-fidelity map of expressed isoforms and fusions to quantify splicing events triggered by treatment. The researchers find strong evidence for drug-induced, coherent splicing changes which disrupt the function of oncogenic proteins, and detect novel transcripts arising from previously unreported fusion events.
A schematic of study design
Three biological replicates of short read RNAseq were generated for untreated (DMSO) and treated (TM) and used for subsequent analysis; long read sequencing were performed for untreated and treated samples. Both technologies were combined for isoform quantification and identification of fusion events.